Summary
Vertex Pharmaceuticals (VRTX) announced significant changes to its senior leadership team on December 2, 2016, aimed at ensuring long-term stability and leadership as the company continues to grow. The most impactful update for investors is the extension of CEO Dr. Jeffrey M. Leiden's employment agreement through March 31, 2020, providing continuity at the executive level. While his base salary and target bonus remain unchanged, the terms for severance and equity vesting upon certain termination events have been adjusted, reflecting a modification in his post-employment compensation structure.
Key Highlights
- 1CEO Dr. Jeffrey M. Leiden's employment agreement extended through March 31, 2020.
- 2Dr. Leiden's annual base salary, target bonus, and equity compensation program remain unchanged.
- 3Severance benefits for Dr. Leiden upon termination without cause or by him for good reason were adjusted.
- 4Cash severance for Dr. Leiden reduced from 200% to 100% of base salary and target bonus.
- 5Partial vesting of Dr. Leiden's equity awards (granted from 2014/2015 onwards) will be based on years of service upon termination, starting at 70% and increasing annually.
- 6Ian F. Smith appointed EVP – Chief Operating Officer and Chief Financial Officer, with an increased base salary and bonus target.
- 7Michael Parini appointed EVP – Chief Legal and Administrative Officer, with an increased base salary.